Skip to main
TNGX

Tango Therapeutics (TNGX) Stock Forecast & Price Target

Tango Therapeutics (TNGX) Analyst Ratings

Based on 11 analyst ratings
Buy
Strong Buy 55%
Buy 36%
Hold 9%
Sell 0%
Strong Sell 0%

Bulls say

Tango Therapeutics is poised for future growth with upcoming catalysts in 2H26, including initial results for their MTA-cooperative PRMT5 inhibitors in lung and CNS cancers. The company's strong pipeline of precision oncology therapies, backed by positive clinical data for its lead asset vopimetostat, positions it well for success in the competitive KRAS and PRMT5 inhibitor market. With a discounted cash flow valuation of $11.6B and a terminal growth rate of 2%, Tango Therapeutics has a target price of $68 per share, indicating significant potential for growth. However, risks to achieving this target include negative clinical results and delays in advancing pipeline candidates.

Bears say

Tango Therapeutics is heavily reliant on the success of its PRMT5 inhibitors TNG462 and TNG456, which are still in early stages of development and may face R&D, regulatory, or commercial setbacks. Additionally, potential competition from already existing or emerging drug candidates targeting similar oncology indications could lower product sales for Tango and lead to dilutive financing transactions, which could have a negative impact on financials. Moreover, safety concerns with potential side effects from associated drugs may dampen physician enthusiasm for the usage of vopimetostat as a treatment option. Lastly, the highly competitive oncology market and the need for continuous financing further add to the company's long-term uncertainty and downside risks.

Tango Therapeutics (TNGX) has been analyzed by 11 analysts, with a consensus rating of Buy. 55% of analysts recommend a Strong Buy, 36% recommend Buy, 9% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Tango Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Tango Therapeutics (TNGX) Forecast

Analysts have given Tango Therapeutics (TNGX) a Buy based on their latest research and market trends.

According to 11 analysts, Tango Therapeutics (TNGX) has a Buy consensus rating as of Sep 12, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $43.18, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $43.18, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Tango Therapeutics (TNGX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.